Clinical Trials

43 enrolled

Multiple Myeloma

NCT03601078 2026-03-04

KarMMa-2

312 enrolled

LymphoidOther hematologic neoplasm

Multiple Myeloma, Recurrence

NCT05283720 2026-03-03

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Phase 2 Recruiting

496 enrolled

Leukemia, Hairy Cell, Lymphoma, Non-Hodgkin, Neoplasms, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT05660967 2026-03-03

EPCORE DLBCL-3

111 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05090566 2026-02-23

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

46 enrolled 15 charts

Multiple Myeloma

NCT07189065 2025-12-16

A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma

Phase 2 Recruiting

150 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04126200 2025-11-06

DREAMM5

208 enrolled

Multiple Myeloma

NCT02719613 2025-06-05

Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

67 enrolled

Multiple Myeloma

NCT00179673 2025-05-13

Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

43 enrolled 16 charts

Lymphoma, Non-Hodgkin

NCT03412565 2025-04-29

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

265 enrolled 21 charts 3 FDA

Multiple Myeloma

NCT05669989 2025-01-23

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

70 enrolled

Multiple Myeloma

NCT04782687 2025-01-16

Study of Selinexor Plus DRd for Newly Diagnosed Multiple Myeloma

73 enrolled

Multiple Myeloma, Neoplasms, Neoplasms, Plasma Cell

NCT05328102 2024-04-30

Phase 2 Study of Plamotamab Combined With Tafasitamab Plus Lenalidomide Versus Tafasitamab Plus Lenalidomide in Relapsed or Refractory (R/R) Diffuse Large-cell B-cell Lymphoma (DLBCL)

3 enrolled 6 charts

Lymphoma, Large B-Cell, Diffuse, Pyloric Stenosis, Hypertrophic

NCT02294357 2023-11-01

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

45 enrolled

Multiple Myeloma, Recurrence

NCT03733691 2023-10-25

Ph 2 Maintenance Trial: Ixazomib vs Ixazomib-Lenalidomide for MM Patients

19 enrolled

Multiple Myeloma

NCT02399085 2023-10-23

L-MIND

81 enrolled 23 charts 2 FDA

Lymphoma, Large B-Cell, Diffuse

NCT02272803 2022-06-22

Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan

82 enrolled 13 charts

Multiple Myeloma

NCT02538965 2020-01-07

A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia

Other hematologic neoplasm

17 enrolled 21 charts

Leukemia, Leukemia, Myeloid, Recurrence, Leukemia, Myeloid, Acute

NCT00655668 2019-11-25

EXPECT

54 enrolled 13 charts

Lymphoma, Non-Hodgkin, Lymphoma, T-Cell

NCT00065351 2019-11-12

Safety and Efficacy of Single-agent CC-5013 in Subjects With Relapsed and Refractory Multiple Myeloma

222 enrolled

Multiple Myeloma, Recurrence

NCT02348528 2019-11-12

Open-label Extended Access Program on Lenalidomide Plus Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma Who Participated in CC-5013-MM021 for at Least 1 Year

65 enrolled

Multiple Myeloma, Recurrence

NCT02159365 2019-07-16

Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients

84 enrolled 11 charts

Multiple Myeloma

NCT01358734 2019-06-25

A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia

Other hematologic neoplasm

88 enrolled 17 charts

Leukemia, Myeloid, Acute

NCT00737529 2018-12-13

EMERGE

134 enrolled 26 charts

Lymphoma, Non-Hodgkin, Lymphoma, Mantle-Cell

NCT00963105 2018-10-31

Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

LymphoidOther hematologic neoplasm

104 enrolled 18 charts

Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT02720510 2018-07-24

PANORAMA4

6 enrolled 7 charts

Multiple Myeloma

NCT01724177 2018-05-29

A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma

LymphoidOther hematologic neoplasm

26 enrolled 15 charts

Leukemia-Lymphoma, Adult T-Cell

NCT01593410 2017-09-20

Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma

194 enrolled

Multiple Myeloma

NCT00413036 2017-03-01

A Study of Revlimid in the Treatment of Non-Hodgkin's Lymphoma

217 enrolled 12 charts

Lymphoma, Non-Hodgkin

NCT00179660 2016-01-21

Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)

50 enrolled 17 charts

Lymphoma, Non-Hodgkin

NCT00908232 2015-01-15

SEQUENTIAL

163 enrolled 11 charts

Multiple Myeloma, Disease Progression, Bone Marrow Neoplasms

NCT00474188 2009-09-02

A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

26 enrolled 5 charts

Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT00179738 2005-11-23

A Multicenter, Single-Arm, Open-Label, Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid, CC-5013) in Subjects With Androgen Independent Prostate Cancer.